Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.
20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion
This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.
Key learning points:
- Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
- Learn about ITM’s implementation journey and considerations when evaluating the technology
- Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).
Don’t miss your chance to learn from experts in the industry – Register for FREE
I think it actually an interesting idea, if public bodies invest in biosimiliarty studies. They could offer low priced medicine to third world countries and cross-finance them by selling the same medicine to first world countries for a higher price. It however would be important that the rational which biosimilars are chosen fur such projects should be as transparent as possible. It would be bad if politicians could take influence on these decisions to harm foreign pharmaceutical companies. Additionally, it would be interesting what happens with the profits gained by this biosimiliar. In the end the WHO could establish itself as a highly subsidized low price pharmaceutical company, which could be a big problem for a large number of privately owned (not subsidized) companies.